. 2018 Feb 12;9:46. doi: 10.3389/fmicb.2018.00046

Table 1.

Cyclodipeptides produced by the newly characterized CDPSs.

CDPS	Species	CDPS subfamily	In vivo activity (BL21 AI-pREP4)^a	UV_214nm area of main compound	Quantity in mg/L culture^b
62	Nocardiopsis potens	NYH	cFM $(30 %)$ , cFF $(30 %)$ , cFA $(19 %)$ , cFY $(8, 4 %)$ , cFL $(7 %)$ , cYA, cFW, cMM, FV, cLM, cLY	2,650	cFM $8.8$ , cFF $7$
63	Streptomyces lavendulae	NYH	cWW $(62 %)$ , cWP $(15, 8 %)$ , cWA $(9, 8 %)$ , cWL $(6, 2 %)$ , cWS $(2 %)$ , cWQ, cWE, cWF,cWC, cWG, cWI, cWN	14,802	cWW $20$
64	Streptomyces purpureus	NYH	cWW $(100 %)$	9,573	cWW $12.7$
65	Nocardiopsis xinjiangensis	NYH	–
66	Actinomadura oligospora	NYH	cFY $(94, 3 %)$ , cYY $(5, 7 %)$	2,729	cFY $6.5$
67	Streptomyces catenulae	NYH	cFY $(99, 9 %)$	1,969	cFY $5.1$
68	Streptomyces sp. NRRL F-5053	NYH	cLW $(97 %)$ , cLL, cFW, cFL	11,431	cLW $13.6$
69	Streptomyces rimosus	NYH	cWY $(98 %)$ , cWW $(2 %)$	11,709	cWY $7$
70	Streptomyces sp. NRRL B-24484	NYH	cWW $(73, 2 %)$ , cWL $(16, 5 %)$ , cWS $(8, 9 %)$ , cWQ, cWF, cWN, cWA,cWP, cWE, cWG	18,457	cWW $39$
71	Strepto. roseochromogenes subsp. Oscitans DS 12.976	NYH	cWY $(98 %)$ , cWA $(2 %)$ , cWS	4,667	cWY $3$
72	Streptomyces sp. AW19M42	NYH	–
73	Streptomyces aureocirculatus	NYH	cWA $(60 %)$ , cWP $(40 %)$	138
74	Streptomyces sp. NRRL S-1868	NYH	cWP $(99, 5 %)$ , cWA, cWS	15,655
75	Streptomyces sp. NRRL F-5123	NYH	cWP $(99, 5 %)$ , cWF, cWG	7,616
76	Streptacidiphilus albus	NYH	–
77	Streptomyces scabrisporus	NYH	cLV $(56, 2 %)$ , cLT $(5, 9 %)$ , cLL $(18 %)$ , cLI $(18, 3 %)$ , cLA	1,715	cLV $5.5$ , cLL $6$ , cLI $6$
78	Kibdelosporangium aridum	NYH	cFG $(100 %)$	51	cFG $< 0.1$
79	Kibdelosporangium aridum	NYH	–
80	Streptomyces natalensis	NYH	–
81	Streptomyces roseoverticilatus	NYH	–
82	Streptomyces varsoviensis	NYH	cPL $(65, 8 %)$ , cPA $(20 %)$ , cPV $(7, 6 %)$ , cPF, cPM, cLL, cLA, cPI, cAA	5,945	cLP $2$
83	Lysobacter antibioticus	NYH	cPR $(100 %)$	140	cPR $4$
84	Allokutzneria albata	NYH	cFI $(100 %)$ , cLI, cMI	54	cFL $0.2$
85	Actineokineospora sp. EG49	XYP	cLI $(65, 7 %)$ , cMI $(9, 1 %)$ , cLL $(5, 4 %)$ , cML $(3, 3 %)$ , cLV $(4, 9 %)$ , cLP $(4, 6 %)$ , cLA $(3, 3 %)$ , cLC, cMV, cMP, cMA, cIA	4,220	cLI^c $46$ , cLL $3.7$
86	Hahella ganghwensis	XYP	cLL $(50, 6 %)$ , cLI $(17, 9 %)$ , cLP $(10, 6 %)$ , cLA $(9, 1 %)$ , cLM $(7 %)$ , cLV $(4, 2 %)$ , cLC, cMI, cLT, cMA, cMP, cLY, cMV	926	cLL $10$ , cLI^c $3.5$
87	Legionella lansingensis	XYP	cGE $(100 %)$	3,121	cGE $14$
88	Geminicoccus roseus	XYP	–
89	Algicola sagamiensis	XYP	cAP $(97 %)$ , cAA $(3 %)$	3,454
90	Parcubacteria bacterium RAAC4_OD1_1	XYP	cHP $(44 %)$ , cHE $(56 %)$	688	cHP $0.4$
91	Methylovulum miyakonense	XYP	cFF $(51, 5 %)$ , cFY $(36, 1 %)$ , cFL $(8, 2 %)$ , cFM $(3, 5 %)$ , cYM	2,786	cFF $6.5$ , cFY $4$ , cFL $1.4$
92	Aminiphilus circumscriptus	XYP	–
93	Fusarium fujikuroi IMI 58289	XYP	–
94	Streptomyces katrae	NYH	cYY $(71, 3 %)$ , cYF $(14, 9 %)$ , cYA $(10, 7 %)$ , cYM $(2 %)$ , cFF, cFA, cYL, cYS	12,312	cYY $29.3$ , cYF $6.6$ , cYA $5.5$
95	Streptacidiphilus melanogenes	NYH	cYY $(59, 6 %)$ , cYA $(22, 2 %)$ , cYF $(16, 3 %)$ , cYM, cFF, cFA, cYL , cYS	11,078	cYY $26.4$ , cYA $12.3$ , cYF $8$
96	Streptomyces sp. PCS3-D2	NYH	cYY $(57, 7 %)$ , cYA $(22, 2 %)$ , cYF $(17, 5 %)$ , cYM, cFF, cFA, cYL	10,901	cYY $26$ , cYA $12.5$ , cYF $8.6$
97	Streptomyces peruviensis	NYH	cYY $(58, 4 %)$ , cYA $(28, 8 %)$ , cYF $(11, 2 %)$ , cYM, cFF, cFA, cYL	10,095	cYY $24$ , cYA $14.8$ , cYF $5$
98	Vibrio sagamiensis	NYH	cPM $(95, 4 %)$ , cMA $(4, 6 %)$ , cPA	6,265	cPM $2.6$
99	Lyngbya confervoides	XYP	–
100	Nocardia concava	NYH	cPP $(100 %)$	1,871
101	Thalassomonas viridans	XYP	cYY $(98 %)$ , cYM $(2 %)$	3,406	cYY $8.1$ , cYM $0.2$
102	Algicola sagamiensis	NYH	cCG $(72, 8 %)$ , cCC $(27, 2 %)$	596
103	Streptomyces sp. HPH0547	NYH	cFL $(91 %)$ , cFM $(7 %)$ , cFF, cYL, cLM	16,190	cFL $21.3$ , cFM $1.6$

Cyclodipeptides produced by BL21 AI-pREP4 expressing the recombinant CDPS; cyclodipeptides are ranked according to the peak area on UV chromatograms recorded at 214 nm (see also Supplemental Data Set 3). Percentages in brackets indicate the proportion of each cyclodipeptides and were calculated from these UV peak areas. The most abundant cyclodipeptide produced is in bold. Cyclodipeptides representing less than 2% are in italic.

Quantities of cyclodipeptide produced are given in gray when standard are available for establishing of calibration curves (see also Supplemental Data Set 2).

cLI quantities were estimated using the calibration curve for cLL.